Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Apala

Showing results (111-120 of 121) with videos related to

Pageof 13
Sort By:
JNCI Cancer Spectrum|February 22, 2023
p27Kip1 V109G as a biomarker for CDK4/6 inhibitors indication in hormone receptor-positive breast cancerSilvana Mouron, Maria J Bueno, Manuel Muñoz, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|November 4, 2022
Corrigendum to "Quantum dots: The cutting-edge nanotheranostics in brain cancer management" [Journal of Controlled Release, Volume 350 (2022) Pages 698-715]Pratik Chakraborty, Sabya Sachi Das, Abhijit Dey, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|September 3, 2022
Quantum dots: The cutting-edge nanotheranostics in brain cancer managementPratik Chakraborty, Sabya Sachi Das, Abhijit Dey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 11, 2019
Randomized Phase 0/I Trial of the Mitochondrial Inhibitor ME-344 or Placebo Added to Bevacizumab in Early HER2-Negative Breast CancerMiguel Quintela-Fandino, Serafín Morales, Alfonso Cortés-Salgado, et al.
Drug Delivery and Translational Research|November 16, 2021
Hydrogel composite containing azelaic acid and tea tree essential oil as a therapeutic strategy for Propionibacterium and testosterone-induced acneAlpna Bisht, Chetna Hemrajani, Charul Rathore, et al.
Mayo Clinic Proceedings|February 4, 2018
Intravenous Bevacizumab for Refractory Hereditary Hemorrhagic Telangiectasia-Related Epistaxis and Gastrointestinal BleedingVivek N Iyer, Dinesh R Apala, Bibek S Pannu, et al.
Aging Cell|January 12, 2026
The Secretome of Human Trophoblast Stem Cells Attenuates Senescence-Associated TraitsKotb Abdelmohsen, Jennifer L Martindale, Martina Rossi, et al.
Breast Cancer Research : BCR|November 12, 2020
Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trialMiguel Quintela-Fandino, Esther Holgado, Luis Manso, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 2, 2026
Design of solubly expressed miniaturized SMART MHCsWilliam L White, Hua Bai, Chan Jhong Kim, et al.
Nature Communications|August 31, 2018
In vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple-negative breast cancerIvana Zagorac, Sara Fernandez-Gaitero, Renske Penning, et al.
Pageof 13

Showing results (111-120 of 121) with videos related to

Sort By:
Pageof 13
JNCI Cancer Spectrum|February 22, 2023
p27Kip1 V109G as a biomarker for CDK4/6 inhibitors indication in hormone receptor-positive breast cancerSilvana Mouron, Maria J Bueno, Manuel Muñoz, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|November 4, 2022
Corrigendum to "Quantum dots: The cutting-edge nanotheranostics in brain cancer management" [Journal of Controlled Release, Volume 350 (2022) Pages 698-715]Pratik Chakraborty, Sabya Sachi Das, Abhijit Dey, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|September 3, 2022
Quantum dots: The cutting-edge nanotheranostics in brain cancer managementPratik Chakraborty, Sabya Sachi Das, Abhijit Dey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 11, 2019
Randomized Phase 0/I Trial of the Mitochondrial Inhibitor ME-344 or Placebo Added to Bevacizumab in Early HER2-Negative Breast CancerMiguel Quintela-Fandino, Serafín Morales, Alfonso Cortés-Salgado, et al.
Drug Delivery and Translational Research|November 16, 2021
Hydrogel composite containing azelaic acid and tea tree essential oil as a therapeutic strategy for Propionibacterium and testosterone-induced acneAlpna Bisht, Chetna Hemrajani, Charul Rathore, et al.
Mayo Clinic Proceedings|February 4, 2018
Intravenous Bevacizumab for Refractory Hereditary Hemorrhagic Telangiectasia-Related Epistaxis and Gastrointestinal BleedingVivek N Iyer, Dinesh R Apala, Bibek S Pannu, et al.
Aging Cell|January 12, 2026
The Secretome of Human Trophoblast Stem Cells Attenuates Senescence-Associated TraitsKotb Abdelmohsen, Jennifer L Martindale, Martina Rossi, et al.
Breast Cancer Research : BCR|November 12, 2020
Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trialMiguel Quintela-Fandino, Esther Holgado, Luis Manso, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 2, 2026
Design of solubly expressed miniaturized SMART MHCsWilliam L White, Hua Bai, Chan Jhong Kim, et al.
Nature Communications|August 31, 2018
In vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple-negative breast cancerIvana Zagorac, Sara Fernandez-Gaitero, Renske Penning, et al.
Pageof 13